Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: A method of producing an artificial neural network capable of predicting the survivability of a patient, including: storing in an electronic database patient health data comprising a plurality of sets of data, each set having at least one of a first parameter relating to heart rate variability data and a second parameter relating to vital sign data, each set further having a third parameter relating to patient survivability; providing a network of nodes interconnected to form an artificial neural network, the nodes comprising a plurality of artificial neurons, each artificial neuron having at least one input with an associated weight; and training the artificial neural network using the patient health data such that the associated weight of the at least one input of each artificial neuron is adjusted in response to respective first, second and third parameters of different sets of data from the patient health data.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Methods and kits for evaluating a clinical outcome of an autoimmune disease, specifically disease flare e.g. if the subject stops taking the biologic disease modifying anti-rheumatic drug (DMARD), by comparing biomarkers of CD45RA, TNF-alpha and/or CXCR5 from CD3+CD4+ T cell population are disclosed. In a specific embodiment, the ratio of first subset of CD3+CD4+CD45RA?TNFA+ (memory) T cells to a second subset comprising CD3+CD4+CD45RA+TNFA+ (naïve) T cell is determined, wherein an increase in the ratio indicates a disease flare state of juvenile idiopathic arthritis (JIA). In another embodiment, enrichment of CD45RA?CR5+ subset among the T cell population indicates likelihood of flare state in JIA via memory persistence enhancement through B cell interaction. In other embodiments, additional markers including IL-6, CCR6, CD152 and PD1 are also determined, and the enrichment of CD45RA-TNFA+IL-6+ subset among the T cell population indicates a likelihood of amplification of the autoimmune disease.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Methods of treating and preventing metabolic disease through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.

Abstract: A subcutaneous implantable device for guiding a vascular access member, the device including a channel defined by a through-hole in the device, wherein the channel is configured to guide the vascular access member there-through to a vascular site; and anchoring means adapted for fixedly attaching, in a form of using suture, tissue ingrowth, tissue encapsulation or tissue adhesion, the device to at least one of a dermis or a subcutaneous tissue at a position underneath the dermis to allow repeated access of the vascular access member through the channel to the vascular site, wherein the device is dimensioned to allow the device to be attached through the anchoring means for anchoring the entire device at a distance away from the vascular site, A method of creating scar tissue track for vascular access is also disclosed where the subcutaneous implantable device for guiding vascular access member is first implanted sub-dermally, the dermis is palpated to feel for the device location and orientation, the guiding

Abstract: According to the present disclosure, a hydrophobic polymeric composite comprising a hydrophobic polymer matrix with hydrophobically modified particles dispersed therein is provided. The hydrophobically modified particles may be derived from hydrophilic particles modified with organic moieties. The hydrophobically modified particles may also take in the form of core-shell fibers with hydrophilic particles encapsulated inside the core of said fibers or in the form of monolithic fibers embedded with hydrophilic particles. The method for making hydrophobic polymeric composite comprising each of the various hydrophobically modified particles is also provided. The hydrophobic polymer matrix can be chosen from poly(alpha-hydroxyesters), of carbonates, polyurethanes or polyalkanoates. For example, hydrophilic particles, such as barium sulphate, zirconium oxide, tantalum oxide or bismuth oxide, are dispersed in the hydrophobic biodegradable polymers, such as poly-(L-lactide) (PLLA).

Abstract: The present disclosure generally relates to an automated method and system for generating a panoramic visualization of a coronary arterial tree of a subject. The method comprises: acquiring an image volume of a thoracic cavity of the subject, the image volume providing a three-dimensional (3D) representation of the thoracic cavity; isolating a coronary structure in the 3D representation by abating one or more other anatomical structures in the thoracic cavity; abating one or more portions of the coronary structure in the 3D representation that attenuate visualization of the coronary arterial tree; generating, by maximum intensity projection (MIP), a plurality of MIP images of the coronary structure from the 3D representation; and compositing the MIP images to generate the panoramic visualization of the coronary arterial tree.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.

Abstract: A probe for iridocorneal angle imaging of an eye, the probe comprising: a distal end having a corneal contact surface; a camera having an imaging lens at the distal end and an imaging axis orthogonal to the corneal contact surface; and at least two illumination sources, each illumination source having an illumination axis at an angle to the corneal contact surface such that the imaging axis and the illumination axes converge in the eye.

Abstract: Methods of treating and preventing kidney injury through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.

Abstract: Methods of treating and preventing hepatotoxicity through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.